ISRCTN76722400进行中（未招募）1 期
Phase I trial: Royal Infirmary Edinburgh Clinical Research Facility code: 003 [The full scientific title will be published within 30 months after the end of the trial]
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
排除标准
- •The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
研究者
相似试验
进行中（未招募）
不适用
An open, randomised clinical Phase I/IIa trial to investigate the maximum tolerated dose, efficacy, safety and pharmacokinetics of repeated three-week courses of a single dose i.v. BI 2536 on day 1 in comparison to single doses i.v. BI 2536 on days 1, 2 and 3 in patients over 60 years of age with refractory or relapsed acute myeloid leukaemia -Male or female patients older than 60 years of age with confirmed AML (except for APL) according to the WHO definition who relapsed after or are refractory to prior chemotherapy. Leukocyte count should be = 25,000 /µl (25 x 109/Liter). Patient should be not eligible for intensive treatment options. Patient should have a life expectancy = 2 months and Eastern co-operative oncology group performance score of 2 or less.MedDRA version: 8.1Level: LLTClassification code 10001941Term: AMEUCTR2006-000613-38-ATBoehringer Ingelheim Austria GmbH60
进行中（未招募）
不适用
An open, randomised clinical Phase I/IIa trial to investigate the maximum tolerated dose, efficacy, safety and pharmacokinetics of repeated three-week courses of a single dose i.v. BI 2536 on day 1 in comparison to single doses i.v. BI 2536 on days 1, 2 and 3 in patients over 60 years of age with refractory or relapsed acute myeloid leukaemiaEUCTR2006-000613-38-DEBoehringer Ingelheim Pharma GmbH & Co. KG60
进行中（未招募）
1 期
Study of safety and efficacy of genome-edited hematopoietic stem and progenitor cells in sickle cell disease (SCD)EUCTR2019-003489-41-ITOVARTIS PHARMA AG30
尚未招募
不适用
A short-term ketogenic diet combined with 24-hour fasting and chemoprotection for patients with acute myeloid leukaemiaacute myeloid leukemiaACTRN12620000850976epean Blue Mountains Local Health District134
已完成
1 期
A Phase I/IIa trial of BT1718 in patients with advanced solid tumours.CancerISRCTN11160449Cancer Research UK66